Nasdaq GlobeNewswire

Amended Summary Notice of Proposed Settlement of The Altair Nanotechnologies, Inc. Shareholder Derivative Litigation




In re Altair Nanotechnologies Shareholder 
Derivative Litigation

CASE NO.: 14-CV-09418-TPG-HBP

RENO, Nev., March 17, 2017 (GLOBE NEWSWIRE) -- PLEASE BE ADVISED that Plaintiffs and the Settling Defendants have reached a settlement (the “Settlement”) to resolve the issues raised in the above-captioned consolidated derivative action (“Action”) (capitalized terms are defined in the Stipulation of Settlement dated July 22, 2016, and Amendment No. 1 to the Stipulation, dated January 18, 2017 (collectively, the “Settlement Stipulation”)).

PLEASE BE FURTHER ADVISED that pursuant to an Order of the United States District Court for the Southern District of New York (the “Court”), a hearing (the “Settlement Hearing”) will be held before the Honorable Thomas P. Griesa in the United States District Court for the Southern District of New York, 500 Pearl Street, Courtroom 26B, New York, New York 10007, at 2:00 p.m. on August 10, 2017, to determine whether (i) the proposed settlement should be approved by the Court as fair, reasonable, adequate, and in the best interests of Altair Nanotechnologies, Inc. (“Altair” or the “Company”) and Altair shareholders; (ii) the Action should be dismissed with prejudice and all Released Claims against the Released Persons should be released and extinguished; (iii) the Court should award attorneys’ fees and expenses to Plaintiffs’ Counsel and incentive awards to Plaintiffs; and (iv) to consider such other matters as may properly come before the Court. The Settlement Hearing may be continued by the Court at the Settlement Hearing, or at any adjourned session thereof without further notice.  The Action and Settlement address claims alleging that certain current and former directors and officers of Altair breached their fiduciary duties by failing to implement and/or maintain adequate internal controls over the Company’s operations and disclosures, by making or approving false statements to the Company’s shareholders, by grossly mismanaging the Company, and by wasting Altair’s assets by causing the Company to incur significant potential liability for legal costs, penalties, fines and/or legal fees in connection with the defense of the Individual Defendants’ unlawful course of conduct. The Action further alleges that certain Defendants were unjustly enriched at the Company’s expense. The Settling Defendants deny and continue to deny all allegations of wrongdoing and deny that Defendants have any liability on the claims asserted in the Action.

As part of the Settlement, Altair has agreed to adopt and/or maintain certain corporate governance reforms as set forth in the Settlement Stipulation. The terms and conditions of the proposed Settlement are set forth in the Settlement Stipulation and Addendum thereto. The Settlement Stipulation and amended Exhibits thereto have been filed with the Court.

Plaintiffs’ Counsel will request Court approval of the agreed upon attorneys’ fees and expenses in an amount not to exceed $150,000, which shall include all attorneys’ fees and costs that may be due any counsel (or anyone else) who has asserted, or participated in the assertion of, derivative claims on behalf of Altair in any court. Any award of fees and expenses will be paid by the Company (or its insurer on its behalf). To date, Plaintiffs’ Counsel have neither received any payment for their services in conducting the Action, nor have counsel been reimbursed for their out-of-pocket expenses incurred. Plaintiffs will also seek Court approval of an incentive payment of up to $1,500 each for their participation and efforts in the Action. This Incentive Amount shall be paid from the attorneys’ fees and expenses awarded by the Court. If the Settlement is approved, the Action will be dismissed with prejudice and the Defendants will be released by Plaintiffs, Altair, and its shareholders from all claims that were or could have been alleged in the Action.

If you are a current Altair Shareholder, you may have certain rights in connection with the proposed settlement. The full and complete Notice along with the Settlement Stipulation  have been made accessible on Altair’s corporate website: If you are a current Altair shareholder and do not take steps to appear in this Action or to object to the Settlement, you will be bound by the Court’s Judgment and Order of Dismissal, you will forever be barred from raising an objection to such Settlement in this or any other action or proceeding, and certain claims that you might have may be released.



Karen Werner,

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Elemica Releases New Connect and Automate Solutions for the Digital Supply Network20.3.2018 13:03Pressemelding

Elemica QuickLink Email P2P and Elemica QuickLink Email Logistics Provides Automated Purchase Order, Invoice, and Shipment Confirmations WAYNE, Pa., March 20, 2018 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Supply Network for process manufacturers, announces new Elemica QuickLink solutions to help clients extend the connection and automation capabilities with their suppliers and logistics providers without requiring time-consuming integration services. The new Elemica QuickLink Email solutions allow clients to onboard their suppliers and logistics service providers cost effectively by connecting and automating their buying and shipping processes through email. Elemica QuickLink Email P2P enables buyers and suppliers to send and confirm purchase orders and invoices automatically with each other, while QuickLink Email Logistics allows shippers to request and confirm shipments with their logistics service providers through email. Supply chain partners that typically use manual proce

Genomatica brings its naturally sourced Brontide(TM) butylene glycol to Europe20.3.2018 13:00Pressemelding

Azelis chosen to distribute; already confirming better personal care formulations SAN DIEGO and ANTWERP, Belgium, March 20, 2018 (GLOBE NEWSWIRE) -- Genomatica, a widely-recognized technology leader for naturally sourced chemicals, and Azelis, a leading distributor of specialty chemicals, announced that Azelis is now the exclusive distributor for personal care applications of Genomatica's naturally sourced, award-winning Brontide(TM) butylene glycol in Europe. Azelis is already seeing widespread interest in Brontide from major brands and plans to support scores of major customers during Brontide's market introduction. See Brontide introduction video. Photos accompanying this announcement are available at A naturally sourced, sustainable cosmetics ingredient; Brontide honored for innovation Butylene glycol, a colo

LexinFintech Holdings Ltd. Reports Fourth Quarter and Full Year 2017 Unaudited Financial Results20.3.2018 12:22Pressemelding

SHENZHEN, China, March 20, 2018 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. ("Lexin" or the "Company") (NASDAQ:LX), a leading online consumer finance platform for educated young adults in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2017. Fourth Quarter and Full Year 2017 Operational Highlights: Total loan originations in 2017 reached RMB47.7 billion, representing an increase of 115% from RMB22.2 billion in 2016. Total outstanding principal balance of loans reached RMB19.3 billion as of December 31, 2017, representing an increase of 94.7% from RMB9.9 billion as of December 31, 2016. The weighted average tenor of loans originated on our platform in 2017 was approximately 9.53 months. The effective APR1 was 22.8% for the fourth quarter of 2017. Customer acquisition cost2 amounted to RMB99 in 2017, representing a decrease of 22% from 127 in 2016. Total number of registered users reached 23.9 million as of December 31, 20

Merus and the Vall d'Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer20.3.2018 12:00Pressemelding

UTRECHT, The Netherlands, March 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), and the Vall d'Hebron Institute of Oncology (VHIO), a leading comprehensive cancer center of excellence located in Barcelona, Spain, today announced a strategic research collaboration to develop novel agents for therapeutic applications. The collaboration will combine Merus' proprietary Biclonics® technology platform and VHIO's expertise in clinical, translational and preclinical research. Josep Tabernero, M.D., Ph.D., M.Sc., Director of VHIO, has served as a scientific advisor to Merus for the past six years. "VHIO is an internationally renowned leader in cancer research. This new collaboration builds on the successful working relationship established in the Phase 1/2 study for MCLA-128, a Biclonics® targeting HER3 signaling, and in the preclinical evaluation of MCLA-158, a Biclonics® target

NIH/NCI Grants Awarded to Inspirata and Case Western Reserve University Projects to Investigate Whole Slide Image Analysis to Predict the Aggressiveness of Certain Cancers20.3.2018 11:13Pressemelding

Multiple academic/industry grants and other funding totaling nearly $10M are being used to develop and validate digital pathology image-based risk predictors for breast, lung and head/neck cancers. If validated, the predictors will help identify which patients have a greater probability of cancer recurrence and a greater need for chemotherapy. Vancouver, BC, March 20, 2018 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that it has been awarded a new National Institute of Health/National Cancer Institute (NIH/NCI) R01 grant with its academic partner, Case Western Reserve University (CWRU) in Cleveland, Ohio. This grant will enable the multidisciplinary team of cancer researchers and physicians to develop and validate an image-based risk predictor of aggressiveness in head & neck cancers based on digitized H&E stained pathology images alone. This 5-year $3.15M Academic Industry Partnership (AIP) R01 grant is in add

Auth0 Announces Key Distribution Partnership with AppXite20.3.2018 10:00Pressemelding

End-to-end identity management now available to all AppXite resellers LONDON, March 20, 2018 (GLOBE NEWSWIRE) -- Auth0, a global leader in Identity-as-a-Service (IDaaS), has announced a new partnership with AppXite, a global leader in SaaS solutions aggregation and fully owned subsidiary of Atea. Auth0's identity and access management platform will be added to AppXite's SaaS offering, adding even more value to its global reseller offering. Auth0's Universal Identity platform will now be accessible to AppXite's extensive global network of managed service providers (MSPs), value-added resellers (VARs), and systems integrators (SIs) around the world. AppXite's reseller network can integrate Auth0's identity platform into their own offering to increase profitability, expand market share, and help their customers thrive in today's cloud economy. "Over the past few years, we have noticed a marked increase in demand for identity management. Companies are realizing the complexity of trying to

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom